Navigation Links
Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
Date:3/13/2013

NEW YORK, March 13, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced the appointment of Amit Sharma , M.D. to the newly created position of Vice President, Medical Affairs.

Amit Sharma , M.D., is an accomplished board certified nephrologist, internist, and hypertension specialist who has a broad-based background in chronic kidney disease and dialysis. Recently, Dr. Sharma was 
Medical Director, Medical Affairs, at Reata Pharmaceuticals.  From 2005-2012, Dr. Sharma served as a Medical Director and Senior Advisor for Liberty Dialysis, LLC, a medium-size dialysis organization with over 300 dialysis clinics.  Liberty was sold 
in 2011 to Fresenius Medical Care AG for $1.7 billion.  From 2001 to 2005, Dr. Sharma served as the Director of the Dialysis Unit and of the Chronic Kidney Disease Clinic for the Naval Medical Center, San Diego.

Dr. Sharma received his medical degree from 
Louisiana State University Medical Center-New Orleans. He completed his 
fellowship in Nephrology and Hypertension from University of California in San Diego in 2001.  Dr. Sharma also has extensive experience conducting
 primary research and as a principal investigator for numerous clinical trials in the field of nephrology and hypertension. He has published in many respected peer reviewed journals and he is a well known presenter for national and international meetings.

Ron Bentsur , the Company's Chief Executive Officer, commented, "We are thrilled to welcome Dr. Sharma
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
3. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
4. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
8. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
11. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... et SAN DIEGO , ... Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) et ... la conclusion d,un accord de fusion définitif en ... totalité des actions ordinaires en circulation d,Ambit Biosciences ... le biais d,une offre publique d,achat qui sera ...
(Date:9/29/2014)... Calif. , Sept. 29, 2014  Bob Pack, ... driver, today called on the California Medical Association to ... Proposition 46 that the San Jose Mercury News called ... "practically everything it wants voters to believe about the ... ad attacks the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... (PRWEB) September 30, 2014 AutoTex ... sporting the iconic pink ribbon in support of breast ... popular month for businesses and non-profits to “go pink” ... cause. , AutoTex PINK is a woman-owned company that ... They are committed to partnering with their customers ...
(Date:9/30/2014)... Minneapolis, MN (PRWEB) September 30, 2014 ... recognized leader in business technology and services was ... in First Call Effectiveness (FCE) in 2013. This ... devices properly the first time and for an ... longevity. For more than 20 years BEI Services ...
(Date:9/30/2014)... Julie Kuriakose, MD; Physician, ... will discuss how restaurants can become more allergy-friendly and ... restrictions at the 2014 Allergy Eats Food Allergy ... 21 in New York City. , “I’m extremely delighted ... such an engaged industry audience. As food allergies become ...
(Date:9/30/2014)... Up to 45% of the population snores ... have sleep apnea. Of these, only 10% have been ... tolerate their prescribed medical device known as CPAP (continuous ... which supports the airway during sleep. , In today’s ... and increasingly difficult to get. Snoring and sleep apnea ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2
... when choosing mates, study finds , MONDAY, June 29 (HealthDay ... a mate, according to a U.S. study that challenges the ... recruited 350 undergraduates for speed-dating events. In half the events, ... in one location. The roles were reversed in the other ...
... ... their perspectives on eye care and safety. , ... Minneapolis, MN (PRWEB) June 29, 2009 -- Stop squinting…proper eye care and ... displays in all their brilliance and clarity., , , The Healthcare Scoop , in recognition ...
... , Two MuGard US Patents Issued , , DALLAS, ... (OTC Bulletin Board: ACCP), announced today that its European partner, ... MuGard in Greece. This follows previous ... license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory ...
... Corporation (Nasdaq: AIRM ), the largest air medical ... a petition with the National Transportation Safety Board (NTSB) requesting ... June 29, 2008 mid-air collision accident in Flagstaff, Arizona. ... to see and avoid the other helicopter on approach to ...
... identified and described a mechanism whereby a single-base change in ... The focus in this study was on a common ... only a slightly increased risk of cancer. However, the risk ... and by almost 100% of African populations. The high ...
... particular can gene raise a man,s risk of familial, or ... disease, according to new research by scientists at the National ... to be identified that affects the risk of familial testicular ... The study appears in the July 2009 Cancer ...
Cached Medicine News:Health News:Maybe Men Aren't So Picky After All 2Health News:The Healthcare Scoop Community Says 'Eye Care' 2Health News:The Healthcare Scoop Community Says 'Eye Care' 3Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 2Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 3Health News:Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 2Health News:Risk of cancer 2Health News:Second gene linked to familial testicular cancer 2Health News:Second gene linked to familial testicular cancer 3
... design permits continuous irrigation through ... the Foley Catheter. 3-Way Catheters ... as well as LUBRICATH coatings, ... of models including Suggs, Emmett, ...
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
Used to provide bladder drainage by percutaneous placement of a balloon catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: